FDA is issuing (Development of Monoclonal Antibody Products Targeting SARS-CoV-2 for Emergency Use Authorization) guidance to provide recommendations to sponsors on the development of monoclonal antibody (mAb) products targeting SARS-CoV-2 intended for the prevention or treatment of COVID-19, including recommendations on addressing the impact of emerging variants.
Discover more from सुदर्शन
Subscribe to get the latest posts sent to your email.